Swiss pharmaceutical giant Novartis AG (NYSE:NVS) reported second-quarter 2025 earnings on Thursday and raised its full-year earnings forecast.
Quarterly sales reached $14.05 billion, almost in line with the analysts’ consensus estimate of $14.06 billion.
Net sales grew 12% year over year (+11% on constant currency or cc) with core operating income up 20% to $5.93 billion (+21% on constant currency).
Also Read: Novartis Gets Swiss Approval For First Malaria Drug For Babies
Sales growth driven by performance from breast cancer treatment, Kisqali ($1.18 billion, +64% cc), Entresto ($2.36 billion, +22% cc), multiple sclerosis drug, Kesimpta ($1.08 billion, +33% cc), Scemblix ($298 million, +79% cc), Leqvio ($298 million, +61% cc), and Pluvicto ($454 million, +30% cc).
Novartis reported adjusted earnings of $2.42 per share, beating the consensus …